Alvimopan + Placebo
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Constipation
Conditions
Constipation
Trial Timeline
Jun 1, 2016 → Dec 1, 2018
NCT ID
NCT02789111About Alvimopan + Placebo
Alvimopan + Placebo is a approved stage product being developed by Merck for Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT02789111. Target conditions include Constipation.
What happened to similar drugs?
20 of 20 similar drugs in Constipation were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03216525 | Phase 3 | Recruiting |
| NCT03068975 | Approved | Terminated |
| NCT02789111 | Approved | Completed |
| NCT02379858 | Pre-clinical | Terminated |
| NCT01704651 | Phase 3 | Completed |
| NCT00708201 | Approved | Completed |
| NCT00256932 | Phase 3 | Completed |
| NCT00241722 | Phase 3 | Completed |
| NCT00135577 | Phase 2 | Completed |
| NCT00101998 | Phase 2 | Completed |
Competing Products
20 competing products in Constipation